As of Jun 27, 2018 Vical Incorporated (NASDAQ:VICL) Sellers Declined Their Shorts By 12.14%

June 27, 2018 - By Robert Judd

Vical Incorporated (NASDAQ:VICL) Corporate Logo

It was reported a decrease on Vical Incorporated (NASDAQ:VICL)’s shorted shares with 12.14%. In June was published VICL’s total 214,900 shorted shares by FINRA. The down change of 12.14% from 244,600 shares was reported. 4 days will cost VICL with 60,800 average volume to recover its previous position. Vical Incorporated float short is 2.71%.

The stock decreased 1.19% or $0.01 during the last trading session, reaching $1.25.Currently Vical Incorporated is downtrending after 29.24% change in last June 27, 2017. VICL has also 16,719 shares volume. VICL underperformed the S&P 500 by 41.81%.

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.The firm is worth $27.16 million. It is developing various DNA vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy.Currently it has negative earnings. The firm also engages in contract manufacturing of plasmid investigational products for various clients.

A couple more Vical Incorporated (NASDAQ:VICL) news were announced by: which released on June 11, 2018 “Vical’s HSV-2 vaccine flunks mid-stage study”, also on June 19, 2018 announced “UPDATE: Vical (VICL) PT Lowered to $3.50 at HC Wainwright”, the next is “Mid-Afternoon Market Update: Dow Rises 80 Points; Nano Dimension Shares Spike Higher” on June 11, 2018. has article titled “Vical: No Compelling Reason To Buy”.

Vical Incorporated (NASDAQ:VICL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: